当前位置: X-MOL 学术J. Genet. Eng. Biotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Journal of Genetic Engineering and Biotechnology Pub Date : 2020-07-28 , DOI: 10.1186/s43141-020-00055-5
Dina B Mahmoud 1 , Zayyanu Shitu 2 , Ahmed Mostafa 3
Affiliation  

The current outbreak of pandemic coronavirus disease 2019 (COVID-19) aggravates serious need for effective therapeutics. Over recent years, drug repurposing has been accomplished as an important opportunity in drug development as it shortens the time consumed for development, besides sparing the cost and the efforts exerted in the research and development process. The FDA-approved antiparasitic drug, nitazoxanide (NTZ), has been found to have antiviral activity against different viral infections such as coronaviruses, influenza, hepatitis C virus (HCV), hepatitis B virus (HBV), and other viruses signifying its potential as a broad spectrum antiviral drug. Moreover, it has been recently reported that NTZ exhibited in vitro inhibition of SARS-CoV-2 at a small micromolar concentration. Additionally, NTZ suppresses the production of cytokines emphasizing its potential to manage COVID-19-induced cytokine storm. Furthermore, the reported efficacy of NTZ to bronchodilate the extremely contracted airways can be beneficial in alleviating COVID-19-associated symptoms. All these findings, along with the high safety record of the drug, have gained our interest to urge conductance of clinical trials to assess the potential benefits of using it in COVID-19 patients. Thus, in this summarized article, we review the antiviral activities of NTZ and highlight its promising therapeutic actions that make the drug worth clinical trials.

中文翻译:

硝唑尼特的药物再利用:它可以成为 COVID-19 的有效疗法吗?

当前爆发的 2019 年大流行性冠状病毒病 (COVID-19) 加剧了对有效疗法的迫切需求。近年来,药物再利用已成为药物开发的重要机遇,因为它可以缩短开发时间,同时节省成本和研发过程中的努力。FDA 批准的抗寄生虫药硝唑尼特 (NTZ) 已被发现对不同的病毒感染具有抗病毒活性,例如冠状病毒、流感、丙型肝炎病毒 (HCV)、乙型肝炎病毒 (HBV) 和其他病毒,表明其具有作为一种广谱抗病毒药物。此外,最近有报道称 NTZ 在小微摩尔浓度下表现出对 SARS-CoV-2 的体外抑制作用。此外,NTZ 抑制细胞因子的产生,强调其管理 COVID-19 诱导的细胞因子风暴的潜力。此外,据报道,NTZ 对极度收缩的气道进行支气管扩张的功效可能有助于缓解 COVID-19 相关症状。所有这些发现,以及该药物的高安全性记录,都引起了我们的兴趣,敦促进行临床试验,以评估在 COVID-19 患者中使用它的潜在益处。因此,在这篇总结文章中,我们回顾了 NTZ 的抗病毒活性,并强调其有希望的治疗作用,使该药物值得临床试验。所有这些发现,以及该药物的高安全性记录,都引起了我们的兴趣,敦促进行临床试验,以评估在 COVID-19 患者中使用它的潜在益处。因此,在这篇总结文章中,我们回顾了 NTZ 的抗病毒活性,并强调其有希望的治疗作用,使该药物值得临床试验。所有这些发现,以及该药物的高安全性记录,都引起了我们的兴趣,敦促进行临床试验,以评估在 COVID-19 患者中使用它的潜在益处。因此,在这篇总结文章中,我们回顾了 NTZ 的抗病毒活性,并强调其有希望的治疗作用,使该药物值得临床试验。
更新日期:2020-07-28
down
wechat
bug